Free Trial
Your $100 Credit Is Waiting! Get MarketBeat All Access Today
Lock In $149
Claim MarketBeat All Access Sale Promotion
Issie Kirby

Issie Kirby Analyst Performance

Director - Medical Technology and Life Sciences Equity Research at Rothschild & Co Redburn

Issie Kirby is a stock analyst at Rothschild & Co Redburn in the medical sector, covering 4 publicly traded companies. Over the past year, Issie Kirby has issued 3 stock ratings, including and hold recommendations. While full access to Issie Kirby's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Issie Kirby's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
5 Last 4 Years
Buy Recommendations
25.00% 1 Buy Ratings
Companies Covered
4 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy25.0%1 ratings
Hold75.0%3 ratings
Sell0.0%0 ratings

Out of 4 total stock ratings issued by Issie Kirby at Rothschild & Co Redburn, the majority (75.0%) have been Hold recommendations, followed by 25.0% Buy.

Exchange Coverage

ExchangePercentageCount
NASDAQ
75.0% of companies on NASDAQ
3 companies
OTCMKTS
25.0% of companies on OTCMKTS
1 company

Issie Kirby, an analyst at Rothschild & Co Redburn, currently covers 4 companies listed on NASDAQ and OTCMKTS, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
4 companies
100.0%

Issie Kirby of Rothschild & Co Redburn specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED INSTRUMENTS
2 companies
50.0%
MED PRODUCTS
2 companies
50.0%

Issie Kirby's Ratings History at Rothschild & Co Redburn

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
4/24/2026Set Price Target$20.68$45.00
Insulet Corporation stock logo
PODD
Insulet
4/24/2026Reiterated Rating$192.21$220.00Neutral
Insulet Corporation stock logo
PODD
Insulet
4/24/2026Downgrade$189.56$220.00Neutral
DexCom, Inc. stock logo
DXCM
DexCom
2/3/2025Upgrade$86.83$115.00Buy